메뉴 건너뛰기




Volumn 50, Issue 8, 2002, Pages 1077-1078

Torsade de pointes probably induced by sparfloxacin

Author keywords

[No Author keywords available]

Indexed keywords

ANTIINFECTIVE AGENT; QUINOLONE DERIVATIVE; SPARFLOXACIN; TUBERCULOSTATIC AGENT;

EID: 0036691959     PISSN: 00045772     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article
Times cited : (4)

References (6)
  • 1
    • 0034728805 scopus 로고    scopus 로고
    • Risk of torsodes de pointes with non-cardiac drugs. Doctors need to aware that many drugs can cause QT prolagation
    • Yap YG, Camm J. Risk of torsodes de pointes with non-cardiac drugs. Doctors need to aware that many drugs can cause QT prolagation. BMJ 2000;320:1158-9.
    • (2000) BMJ , vol.320 , pp. 1158-1159
    • Yap, Y.G.1    Camm, J.2
  • 2
    • 0030175084 scopus 로고    scopus 로고
    • Sparfloxacin worldwide in vitro literature: Isolated data available through 1994
    • Cohen MA, Yoder SL, Talbot GH. sparfloxacin worldwide in vitro literature: isolated data available through 1994. Diagn Microbiol Infect Dis 1996;25:53-64.
    • (1996) Diagn Microbiol Infect Dis , vol.25 , pp. 53-64
    • Cohen, M.A.1    Yoder, S.L.2    Talbot, G.H.3
  • 3
    • 0029951373 scopus 로고    scopus 로고
    • Overview of electrocardiographic and cardiovascular safety data for sparfloxacin. Sparfloxacin Safety Group
    • Jaillon P, Morganroth J, Brumpt I, Talbot G. Overview of electrocardiographic and cardiovascular safety data for sparfloxacin. Sparfloxacin Safety Group. J Antimicrob Chemother 1996;37(Suppl A): 161-7.
    • (1996) J Antimicrob Chemother , vol.37 , Issue.SUPPL. A , pp. 161-167
    • Jaillon, P.1    Morganroth, J.2    Brumpt, I.3    Talbot, G.4
  • 4
    • 0030897674 scopus 로고    scopus 로고
    • Sparfloxacin. A review of its antibacterial activity, pharmacokinetic properties, clinical efficacy and tolerability in lower respiratory tract infections
    • Goa KL, Bryson HM, Marknam A, Sparfloxacin. A review of its antibacterial activity, pharmacokinetic properties, clinical efficacy and tolerability in lower respiratory tract infections. Drugs 1997;53:700-25.
    • (1997) Drugs , vol.53 , pp. 700-725
    • Goa, K.L.1    Bryson, H.M.2    Marknam, A.3
  • 5
    • 0031881199 scopus 로고    scopus 로고
    • Sparfloxacin but not levofloxacin or ofloxacin prolonges cardiac repolarization in rabbit purkinje fibres
    • Adamantidis MM, Dumotier BM, Caron JF, Bordet R. Sparfloxacin but not levofloxacin or ofloxacin prolonges cardiac repolarization in rabbit purkinje fibres. Fundam Clin Pharmacol 1998;12:70-6.
    • (1998) Fundam Clin Pharmacol , vol.12 , pp. 70-76
    • Adamantidis, M.M.1    Dumotier, B.M.2    Caron, J.F.3    Bordet, R.4


* 이 정보는 Elsevier사의 SCOPUS DB에서 KISTI가 분석하여 추출한 것입니다.